What does Damora Therapeutics, Inc. do?
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia;…
What is Damora Therapeutics, Inc.'s P/E and P/B ratio?
Damora Therapeutics, Inc. has a P/E ratio of -86.8 and a P/B ratio of 2.60.
What is Damora Therapeutics, Inc.'s debt-to-equity ratio?
Damora Therapeutics, Inc. has a debt-to-equity ratio of 0.00.
How much does Damora Therapeutics, Inc. owe compared with what it owns?
Damora Therapeutics, Inc. owes $0.05 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Damora Therapeutics, Inc.'s Positivity rank?
Damora Therapeutics, Inc. is ranked #4,120 of 6,775 companies globally and #1,965 of 4,000 in United States on PositoAI, with a Positivity Score of 19,919.
Does Damora Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
Damora Therapeutics, Inc. has no active red flags. It has 1 yellow flag (PosiYellow stress signals, 2/10 points): Change of auditor (8-K Item 4.01).
Where can I read the latest news about Damora Therapeutics, Inc.?
Recent headlines about Damora Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Damora Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Damora Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.